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Abstract
Background: Human skin is able to mount a fast response against invading microorganisms by the release of antimicrobial
proteins such as the ribonuclease RNase 7. Because RNase 7 exhibits high activity against Enterococcus faecium the aim of
this study was to further explore the role of RNase 7 in the cutaneous innate defense system against E. faecium.
Methodology/Principal Findings: Absolute quantification using real-time PCR and ELISA revealed that primary
keratinocytes expressed high levels of RNase 7. Immunohistochemistry showed RNase 7 expression in all epidermal layers
of the skin with an intensification in the upper more differentiated layers. Furthermore, RNase 7 was secreted by
keratinocytes in vitro and in vivo in a site-dependent way. RNase 7 was still active against E. faecium at low pH (5.5) or high
NaCl (150 mM) concentration and the bactericidal activity of RNase 7 against E. faecium required no ribonuclease activity as
shown by recombinant RNase 7 lacking enzymatic activity. To further explore the role of RNase 7 in cutaneous defense
against E. faecium, we investigated whether RNase 7 contributes to the E. faecium killing activity of skin extracts derived
from stratum corneum. Treatment of the skin extract with an RNase 7 specific antibody, which neutralizes the antimicrobial
activity of RNase 7, diminished its E. faecium killing activity.
Conclusions/Significance: Our data indicate that RNase 7 contributes to the E. faecium-killing activity of skin extracts and
suggest an important role for RNase 7 in the protection of human skin against E. faecium colonization.
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Introduction
Human skin is continuously exposed to a wide variety of
potential pathogenic bacteria. Despite these threats, human skin is
normally not infected. In the last decade it has become evident
that human skin provides, in addition to its physical barrier, also a
chemical barrier based on the release of antimicrobial proteins [1–
3]. Antimicrobial proteins are endogenous, gene-encoded proteins,
which are able to kill bacteria, fungi and viruses at micro- and
nanomolar concentrations. Recent in vivo studies confirmed the
hypothesis that antimicrobial proteins have the capacity to protect
the host against pathogenic microorganisms [4–6]. Some of these
antimicrobial proteins are upregulated at sites of infection and
inflammation such as the human beta-defensins 22 and 23 (hBD-
2, hBD-3) as well as the cathelicidin LL-37 [3,7–9]. Upregulation
of hBD-2, hBD-3 and LL-37 in the skin provides a rapid first-line
of cutaneous defense against invading microorganisms [10–17].
Other antimicrobial proteins such as psoriasin (S100 A7) are also
expressed in high amounts in healthy skin [18]. Psoriasin is mainly
active against the gram-negative bacterium E. coli and we recently
presented evidence that psoriasin is key for the resistance of
human skin against colonization by the gram-negative gut
bacterium E. coli [18].
Another antimicrobial protein expressed in healthy skin is
RNase 7. RNase 7 is a member of the RNase A superfamily that is
characterized by homology with bovine ribonuclease A [19].
Members of this family share a conserved structure of six or eight
cysteines linked by disulfide bonds and two histidines and one
lysine that form the catalytic site [19]. To date, eight human
members (RNase 1–8) of the RNase A superfamily have been
described. Moreover, five additional genes in the human genome
that are related to the RNase A ribonucleases have also been
identified (RNase 9–13) [19]. However, the physiological role of
these ribonucleases is still not well understood. Recent data suggest
that ribonucleases may also play a role in host defense. Eosinophil-
derived neurotoxin (EDN; RNase 2) and eosinophil cationic
protein (ECP; RNase 3) are localized to eosinophil secretory
granules and exhibit antiviral activities [20,21]. In addition, ECP
displays in vitro killing activity against various gram-negative and
gram-positive bacteria [22]. Antimicrobial activity was also
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6424reported for RNase 5 (Angiogenin) [23], a protein which was
originally identified from its capacity to induce blood vessel growth
[24]. RNase 7 was originally isolated from stratum corneum
extracts and cloned from keratinocytes [25]. It exhibited a broad-
spectrum of antimicrobial activity [25]. Zhang et al. isolated the
RNase 7 gene by a genomic database search [26]. RNase 7
mRNA expression was detected in primary keratinocytes and
expression was induced by contact with heat-killed bacteria and
UV-B radiation [25,27]. Recently, induction of RNase 7 mRNA
expression has been reported in skin biopsies of psoriasis and
atopic dermatitis patients [28].
The aim of this study was to further assess the role of RNase 7 in
cutaneous defense. A detailed analysis of its in vitro as well as in vivo
expression together with functional antimicrobial studies suggest
that RNase 7 may play a major role in skin defense and
contributes to the high resistance of human skin against
colonization with the gram-positive gut bacterium E. faecium.
Results
Generation of RNase 7-specific antibodies
First, we successfully expressedR N a s e7i nr e c o m b i n a n tf o r m
in E. coli. The serum of a goat immunized by a mixture of natural
and recombinant RNase 7 showed high RNase 7 immunoreac-
tivity. Purification of RNase 7 antibodies from the serum using
an RNase 7 affinity column led to the isolation of RNase 7
specific antibodies. These antibodies specifically detected RNase
7 in stratum corneum extracts (Fig. 1A). For quantitative
a n a l y s e sa n dt od e t e r m i n eh o wR N a s e7i ss e c r e t e din vivo at
different skin sites, we developed an RNase 7-specific enzyme-
linked immunosorbent assay (ELISA) using the RNase 7-specific
polyclonal antibodies. Fig. 1B shows a representative standard
curve using different concentrations of RNase 7. The detection
limit of the ELISA was at a concentration of 0.3 ng?ml
21.T h e
specificity of the RNase 7 antibodies was further verified by
testing other cationic antimicro b i a lp r o t e i n ss u c ha sl y s o z y m e ,
hBD-2, hBD-3 and the closely related (78% identity) RNase 8
[29]. All these proteins were not detected by the RNase 7 ELISA
(not shown).
Primary keratinocytes express high levels of RNase 7
mRNA
We used real-time PCR to determine the absolute transcript
levels in primary keratinocytes. This quantitative analysis revealed
that primary keratinocytes expressed high levels of RNase 7 mRNA
when compared to other skin-derived antimicrobial proteins such as
human beta-defensin-2 (hBD-2), psoriasin and LL-37 (Fig. 2A).
RNase 7 is secreted in vitro and in vivo
To study whether RNase 7 is secreted by keratinocytes, we
analyzed keratinocyte culture supernatants as well as cell extracts by
ELISA. High amounts (3–18 ng/1.5610
5 cells) of RNase 7 were
detected in the supernatants of primary keratinocytes cultured for
16 h indicating that RNase 7 is efficientlysecreted bythe keratinocytes
(Fig. 2B). A comparison of RNase 7 amounts present in the culture
supernatants and cell extracts derived from primary keratinocytes
revealed that the main portion of RNase 7 is released (Fig. 2C). To
determine whether RNase 7 is secreted in vivo, we investigated the
presence of RNase 7 at various skin surface sites. We rinsed
standardized 0.5-cm
2 skin areas of healthy human donors with
500 ml 10 mM sodium phosphate buffer containing 150 mM NaCl,
pH 7.4 and analyzed the washing fluids for their content of RNase 7
by ELISA. RNase 7 amounts at skin surfaces depended on the donor
(n=10), the skin area, and previous washings for body care. RNase 7
amountsweremainlyintherangebetween0.3and3 ng?cm
22(Fig.3).
In addition, we investigated the concentration of RNase 7 in perianal
swabs derived from six individuals. In all six samples RNase 7 was
detectable (range of 3.9–12.2 ng?ml
21; not shown).
RNase 7 is expressed in all epidermal layers of human
skin
To investigate the distribution of RNase 7 in healthy skin in vivo,
we performed immunohistochemistry using the RNase 7-specific
antibodies. Intense RNase 7 immunoreactivity was present in all
epidermal layers of the skin with an intensification of the upper
more differentiated layers, especially within stratum corneum.
Sebaeceous glands and hair follicles also stained positively. The
outer root sheath of hair follicles showed more intensive
immunoreactivity when compared to the inner root sheath (Fig. 4).
Figure 1. Generation of RNase 7 specific antibodies and ELISA. (A) A goat was immunized with a combination of natural and recombinant
RNase 7, and serum was purified with an RNase 7 affinity column. The specificity of the RNase 7 affinity-purified polyclonal antibodies was verified by
Western-Blot analysis. 100 mg of stratum corneum extract and different amounts of natural skin-derived RNase 7 and recombinant RNase 7 were
subjected to Western-Blot analysis using the affinity-purified polyclonal antibodies raised against RNase 7. (B) The RNase 7 antibodies were used to
establish an ELISA as described in the experimental procedures. A representative standard curve of the RNase 7 ELISA is shown. The detection limit of
the ELISA was a concentration of 0.3 ng?ml
21 RNase 7.
doi:10.1371/journal.pone.0006424.g001
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against E. faecium
To verify the antimicrobial activity of RNase 7 against E.
faecium, we investigated natural RNase 7 for microbicidal activity
in an antimicrobial microdilution assay against E. faecium (ATCC
6057). This strain was effectively killed by RNase 7 (lethal dose of
90% (LD90)=0.4–0.8 mg?ml
21; not shown). To further support
the idea of an antimicrobial function for RNase 7 in cutaneous
defense, we performed antimicrobial assays in buffers with variable
pH (5.5, 6.5 and 7.4). RNase 7 was active under all pH conditions
(Fig. 5). In addition, E. faecium was also effectively killed by RNase
7 at 150 mM NaCl (Fig. 5).
The activity of RNase 7 against E. faecium requires no
enzymatic activity
To assess whether the ribonuclease activity of RNase 7 might be
responsible for its antibacterial activity, we expressed recombinant
RNase 7 containing two mutated amino acids in its active site
required for enzymatic activity. As shown in Fig. 6A, mutated
RNase 7 exhibited no ribonuclease activity whereas the recom-
binant wildtype RNase 7 showed high ribonuclease activity.
However, when tested against E. faecium, no differences in the
killing activity of wildtype and mutated RNase 7 were observed,
suggesting that the ribonuclease activity of RNase 7 is not
necessary for its antibacterial activity (Fig. 6B). Similar results were
obtained with E. coli (not shown).
RNase 7 contributes to the killing activity of human
stratum corneum extracts against E. faecium and faecalis
To analyze whether RNase 7 contributes to the Enterococcus–
killing activity of healthy skin, we determined whether antibodies
to RNase 7 affected the killing of E. faecium in skin extracts derived
from stratum corneum. First, we analyzed whether RNase 7
antibodies neutralized the antibacterial activity of RNase 7 against
E. faecium. For this purpose we tested the activity of RNase 7
against E. faecium in an antibacterial microdilution assay in the
presence of RNase 7 antibodies. Fig. 7A shows that application of
the RNase 7 antibodies completely blocked the E. faecium-killing
Figure 2. Abundant expression and secretion of RNase 7 in primary keratinocytes. (A) Transcript levels quantified by real-time PCR of
various antimicrobial proteins expressed in primary keratinocytes. Shown is the range of data obtained in three independent experiments measured
in triplicate. (B) Secretion of antimicrobial proteins from keratinocytes cultured for 16 h. Supernatants of primary keratinocytes were analyzed for
RNase 7, psoriasin and hBD-2 by ELISA. Shown is the range of data obtained by three independent experiments measured in triplicate. (C)
Comparison of RNase 7 protein present in cell extracts with supernatants from primary keratinocytes cultured for 16 h. Shown are the results of three
independent cell culture samples (columns represent means6S.D.).
doi:10.1371/journal.pone.0006424.g002
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equivalent concentrations of irrelevant antibodies (antibodies
derived from goat preimmune serum) were used. Having
established that the RNase 7-specific antibodies neutralized the
antimicrobial effect of RNase 7, we used this approach to
investigate the role of RNase 7 for the killing activity of human
skin extracts. The application of the RNase 7-blocking antibodies
to skin extracts derived from stratum corneum before inoculation
with E. faecium resulted in a substantial increase in E. faecium
growth (Fig. 7B).
Discussion
There is increasing evidence that the skin and other epithelial
layers are protected from infection by the release of antimicrobial
proteins. Many studies indicate that antimicrobial proteins, like the
Figure 3. RNase 7 is secreted in vivo on the body surface. Standardized areas of various body locations on healthy volunteers (n=10) were
rinsed with 10 mM sodium phosphate buffer containing 150 mM NaCl, pH 7.4 to determine the concentration of RNase 7 at the skin surface by ELISA.
Data represent the amount of soluble RNase7/cm
2. Each symbol represents data from a single volunteer.
doi:10.1371/journal.pone.0006424.g003
Figure 4. Epidermal keratinocytes express RNase 7 in vivo. (A & B) Immunostaining of RNase 7 expression in human normal skin using affinity-
purified RNase 7 antibodies. Strong RNase 7 immunoreactivity was detected in the epidermis with highest activity in the uppermost epidermal layers.
Sebaecous glands and hair follicles also stained positively. (A) 106magnification, (B) 20 X magnification of the indicated area of panel A. (C) Negative
control using preimmune serum. (E: Epidermis, SC: Stratum Corneum, HF: Hair Follicle, I: Infundibulum, SG: Sebaceous Gland, DP: Dermal Papilla, ORS:
Outer Root Sheath, IRS: Inner Root Sheath)
doi:10.1371/journal.pone.0006424.g004
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psoriasin (S100A7), play an important role in cutaneous defense
[1,3]. Although several reports suggest that the human RNase A
superfamily members ECP (eosinophil cationic protein, RNase 3)
and EDN (eosinophil-derived neurotoxin, RNase 2) are important
effector molecules of eosinophilic granulocytes [30,31], the role of
RNases in epithelial defense is largely unknown. A recent study
indicates that a mouse ribonuclease (angiogenin 4) may participate
in regulating the intestinal microflora [23].
The recent isolation of the antimicrobial ribonuclease RNase 7
from stratum corneum of healthy skin prompted us to further
analyze its role in cutaneous defense. A quantitative analysis
revealed that primary keratinocytes express high levels of RNase 7
mRNA when compared to other skin-derived antimicrobial
proteins such as psoriasin, hBD-2, and LL-37. This observation
further strengthened the hypothesis that RNase 7 may be an
important defense molecule in cutaneous innate immunity. To get
further insight into RNase 7 protein expression, we generated
RNase 7 specific antibodies. Immunohistochemistry using these
novel antibodies revealed expression of RNase 7 in all layers of
human epidermis with higher intensity in the more outer
differentiated epithelial layers. Hair follicles also stained positively
which is in concordance with a recent study demonstrating RNase
7 expression in hair follicle epithelium [32]. The expression of
RNase 7 in the uppermost epidermal layers and its expression in
hair follicles are in concordance with its proposed antimicrobial
function, because it is expressed at areas where the first contact
with bacteria takes place. Because the deduced RNase 7 precursor
contains a signal sequence, we hypothesized that RNase 7 may be
efficiently secreted by keratinocytes. Using an RNase 7-ELISA,
that we developed, we were able to detect higher RNase 7 protein
levels in the supernatants of the primary keratinocyte cultures
compared with keratinocyte extracts. These data indicate that
RNase 7 is secreted from viable cells and acts primarily outside the
cell, which is consistent with the proposed role of RNase 7 in
antimicrobial defense.
Based on these in vitro data, we speculated that RNase 7 is
secreted in vivo on the body surface. To prove this hypothesis, we
determined whether RNase 7 is present at various skin surface
sites. We were able to recover various amounts of RNase 7 in skin
washing fluids from different body sites, which confirmed that
RNase 7 is secreted in vivo. High variability in RNase 7 secretion
levels was detected in different persons and skin locations. This
suggests that levels of RNase 7 secretion may depend on
environmental factors such as microbial colonization.
We recently identified psoriasin as a principal E. coli–killing
factor that protects the skin from infections with the gut bacterium
E. coli [18]. However, the high expression of RNase 7 in skin and
its very potent activity against E. faecium [25] suggest that the skin is
also protected against colonization with E. faecium. This would
explain the low infection rate of skin areas exposed to E. faecium
such as the perianal region. To prove this hypothesis, we first
explored whether the skin has the capacity to kill E. faecium. Skin
extracts derived from the stratum corneum efficiently killed E.
faecium indicating that the skin harbors defense mechanisms which
inhibit cutaneous colonization with E. faecium. To further evaluate
whether RNase 7 might contribute to these defense mechanisms,
we specifically inhibited the antimicrobial activity of RNase 7 in
the skin extracts using RNase 7-specific antibodies. These
experiments revealed that RNase 7 contributes to the E. faecium
killing activity of skin extracts, suggesting an important role for
RNase 7 in protecting the skin against E. faecium infection.
Figure 5. Antimicrobial activity of RNase 7 against E. faecium at
various pH and high salt conditions. The antimicrobial activity of
RNase 7 (1.6 mg?ml
21) was tested in a microdilution assay against E.
faecium (ATCC 6057) at various pH conditions or in the presence of
150 mM NaCl. Results are from triplicate determinations and presented
as the mean6S.D.
doi:10.1371/journal.pone.0006424.g005
Figure 6. Bactericidal activity of RNase 7 requires no enzymatic activity. (A) Shown are the ribonuclease activities of wildtype non-mutated
recombinant RNase 7 (wt R7) and mutated recombinant RNase 7 containing the double mutation, histidin-123 to aspartate and lysine-38 to arginine
(mut R7). n.d.=not detectable. (B) The antimicrobial activity of wildtype recombinant RNase 7 (wt R7) and ribonuclease-deficient RNase 7 (mut R7)
were tested at concentrations of 20 and 1.5 mg?ml
21 against E. faecium (ATCC 6057). Data are means6S.D.
doi:10.1371/journal.pone.0006424.g006
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raises the question of the responsible molecular killing mecha-
nisms. We speculated that the high ribonuclease activity of RNase
7 might be involved in the RNase 7-mediated killing of E. faecium.
To address this question, we generated recombinant RNase 7 that
lacks enzymatic activity. By making point mutations of the
catalytic residues lys-38 and his-123, we found that ablation of
ribonuclease activity had no impact on the bactericidal activity of
RNase 7 against E. faecium. This is consistent with other reports
showing that members of the RNase A superfamily exhibit
ribonuclease-independent antibacterial activity [33–35], but raises
the question of the role of the enzymatic activity. It has been
shown that the antiviral activity of the RNases ECP and EDN
against respiratory syncytial virus (RSV) requires functional
ribonuclease activity [20,21]. These data suggest that the
ribonuclease activity of RNase 7 may be necessary for a potential
antiviral rather than antibacterial activity. However, this remains
to be proven as it is not yet known whether RNase 7 exhibits
antiviral activity.
Recently, it has been reported that the ribonuclease inhibitor
interacts with RNase 7 and blocks its ribonuclease as well as
antimicrobial activity [36]. It is possible that the ribonuclease
inhibitor masks the amino acid residues responsible for the
antimicrobial action of RNase 7. Another explanation is that the
interaction of the ribonuclease inhibitor RI induces a conforma-
tional change of RNase 7 as recently reported for the interaction of
RNase 1 and the ribonuclease inhibitor [37].
RNase 7 is a highly cationic protein with a pI of approximately
10.7. Many human antimicrobial proteins are cationic and contain
a large number of basic amino acids. Examples comprise the
alpha- and beta-defensins, the cathelicidins as well as the histatins
[7,38,39]. It is believed that the highly cationic character of these
molecules results in a high affinity to the negatively charged
surface of bacteria, which is prerequisite for efficient killing [40].
Very recently, Huang and colleagues showed by NMR and
mutagenesis studies that cationic lysines are critical for the
antimicrobial activity of RNase 7 against P. aeruginosa. They
suggested that RNase 7 may bind to the negatively charged
components of the bacterial membrane through the presence of
cationic residues which ultimately leads to membrane disruption
[34]. It remains to be shown whether this killing mechanism,
which has been proposed for many antimicrobial peptides [40], is
also responsible for the high killing activity of RNase 7 against E.
faecium.
In summary, our data suggest that RNase 7 contributes to
cutaneous innate immunity against E. faecium and probably other
bacteria. An interesting speculation is that dysregulation of RNase
7 may result in higher susceptibility to infectious diseases. A better
understanding of the role of endogenous antimicrobial proteins
such as RNase 7 may result in the development of novel
therapeutic strategies that enhance the cutaneous innate defense
system by the application or selective induction of antimicrobial
proteins.
Materials and Methods
Ethics Statement
All experiments were performed according to the Declaration of
Helsinki protocols and under protocols approved by the Ethics
Committee at the Medical Faculty of the Christian-Albrechts-
University, Kiel, Germany (A104/06).
Culture of epithelial cells
Keratinocytes were derived from foreskin samples obtained
from circumcision surgery after obtaining written informed
consent. The protocol was approved by the Ethics Committee at
the Medical Faculty of the Christian-Albrechts-University, Kiel,
Germany. Foreskin-derived primary keratinocytes were isolated
from foreskins as described [41] and cultured in Epilife-medium
(Sigma) in a humidified atmosphere with 5% CO2. For stimulation
experiments, cells were seeded in 12-well tissue culture plates
(3.8 cm
2?well
21, BD Biosciences) and used at 60-80% confluence.
RNA isolation and cDNA synthesis
After treatment, cells were washed twice with PBS and
harvested using TRIzol reagent (Invitrogen, San Diego, CA)
according to the supplier’s protocol. RNA quality and quantity
were determined by gel electrophoresis and photometry. Subse-
Figure 7. RNase 7 contributes to the killing activity of human
stratum corneum extracts against E. faecium. (A) RNase 7
(12.5 mg?ml
21) was tested in a microdilution assay against E. faecium
(ATCC 6057) alone (R7) or in the presence of 10 mg?ml
21 RNase 7
antibodies (R7+R7-Ab). Application of the RNase 7 antibodies com-
pletely blocked the E. faecium-killing activity of RNase 7. As a control,
RNase 7 was incubated with irrelevant goat antibodies (R7+irr.Ab). Both,
RNase 7 antibodies (R7-Ab) alone as well as irrelevant antibodies (irr.
Ab) alone did not influence the growth of E. faecium. (B) The killing
activity of skin-extracts derived from stratum corneum against E.
faecium was tested. 2 h incubation of E. faecium with stratum corneum
extract revealed high killing activity of the extract against E. faecium
(s.c.). In contrast, the application of RNase 7-blocking antibodies to the
stratum corneum extract significantly reduced the killing activity of the
extract (s.c.+ R7-specific Ab; p,0.01, Student’s t-test). Incubation of the
stratum corneum extract with the irrelevant antibodies did not affect
the killing activity of the extracts (s.c.+ irrelevant Ab). Data show
means6S.D. of triplicate samples. A representative result of three
independent experiments is shown.
doi:10.1371/journal.pone.0006424.g007
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oligo dT- primers and 50 Units Superscript II (Invitrogen)
according to the manufacturer’s protocol.
Real-time PCR
Real-time PCR analyses were performed in a fluorescence
thermal cycler (LightCycler; Roche Diagnostics GMBH). cDNA
corresponding to 10 ng RNA served as a template in a 10 ml
reaction containing 0.5 mM of each primer and 1 x SYBR Premix
Ex Taq mix (TaKaRa). Samples were loaded into capillary tubes
and incubated in the fluorescence thermal cycler (LightCycler) for
an initial denaturation at 95uC for 10 min followed by 45 cycles,
each cycle consisting of 95uC for 15 s, 60uC (touchdown of
21uC?cycle
21 from 66uCt o6 0 uC) for 5 s and 72uC for 10 s. At
the end of each run, melting curve profiles were produced by
cooling the sample to 65uC for 15 s and then heating slowly at
0.20uC?s
21 up to 95uC with continuous measurement of
fluorescence to confirm amplification of specific transcripts.
Cycle-to-cycle fluorescence emission readings were monitored
and analyzed using LightCycler Software (Roche Diagnostics
GMBH). The specificity of the amplification products was further
verified by subjecting the amplification products to electrophoresis
on a 2% agarose gel. The fragments were visualized by ethidium
bromide staining and the specificity of PCR products was verified
by sequencing of representative samples. The following intron
spanning primers were used: RNase-7 59- GGA GTC ACA GCA
CGA AGA CCA -39 (forward primer) and 59- CAT GGC TGA
GTT GCA TGC TTG A -39 (reverse primer); hBD-2 59- GCC
TCT TCC AGG TGT TTT TG -39 (forward primer) and 59-
GAG ACC ACA GGT GCC AAT TT -39 (reverse primer);
psoriasin 59- AGA CGT GAT GAC AAG ATT GAC -39 (forward
primer and )59- TGT CCT TTT TCT CAA AGA CGT C -39
(reverse primer); LL-37 59-GGG GCT CCT TTG ACA TCA GT
-39 (forward primer) and 59- TGG GTA CAA GAT TCC GCA
AA -39 (reverse primer). Standard curves were obtained for each
primer set with serial dilutions of plasmids containing the
amplification product. Absolute transcript levels are shown per
10 ng total RNA.
Expression of recombinant RNase 7 in E. coli
The cDNA encoding the 128 amino acids containing natural
form of RNase 7 was cloned into the expression vector pET-32a
(Novagen), which contains an N-terminal His-Tag sequence
allowing purification of the fusion-protein by the use of a nickel-
affinity column. A 200 ml culture of transformed E. coli (strain
BL21pLysS, Novagen) was grown to an optical density of 0.6 and
expression was induced by adding 1 mM IPTG. Expression was
carried out for 3 h and bacteria were harvested by centrifugation
at 6000 x g for 5 min and lysed by sonication. Extracts were
purified with a nickel-affinity column (Macherey-Nagel) followed
by C8 reversed-phase HPLC as described for the purification of
human beta-defensin-3 [42]. The N-terminal part of the purified
fusion protein was cleaved off by enterokinase (Invitrogen) and the
resulting mature 128 amino acids containing RNase 7 protein was
purified by C2/C18 reversed phase HPLC as previously described
[42]. Mass analysis using electrospray ionization mass spectrom-
etry (QTOF-II Hybrid-mass spectrometer; Micromass) yielded a
mass of 14,546 Da, which exactly corresponds to the mass of
natural RNase 7 [25].
Recombinant RNase 7 without ribonuclease activity was
generated by site-directed mutagenesis to introduce mutations in
the active center of RNase 7. First, histidin at position 123 was
mutated to aspartate using the following primer: sense 59- ACT
GAG ATC TGG GTA CCG ACG ACG ACG ACA AGA AGC
CCA AGG GCA TGA CCT C -39, antisense 59- ATT TGC
GGC CGC CTA AAG GAC TCT GTC CAA GTC TAC AGG -
39. The resulting PCR product was digested with the restriction
enzymes NOTI and BglII and subsequently cloned into the
expression vector pET-32a. This plasmid was used as a template
to mutate lysine at position 38 to arginine using the ‘‘QuikChange
Multi Site-Directed Mutagenesis Kit’’ (Stratagene) and the
following primers: 59- GCA CAC AAA ACG GTG CAG AGA
CCT CAA CAC C 39, antisense 59- GGT GTT GAG GTC TCT
GCA CCG TTT TGT GTG C- 39. The mutated plasmids were
used for expression in E. coli as described above. The correct mass
of the resulting protein was verified by electrospray ionization
mass spectrometry.
Generation of RNase 7-specific antibodies
0.5 mg natural skin-derived RNase 7 was mixed with 1.3 mg
recombinant RNase 7 and the resulting 1.81mg were used for
immunization. 1.2 mg of this RNase 7 preparation was conju-
gated to keyhole limpet hemocyanine (KLH, Sigma) using
glutaraldehyde. Therefore, 1 mg KLH in 1 ml PBS was mixed
with 1 ml 25% glutaraldehyde (Serva) and incubated for 1 h at
room temperature with gently shaking. After incubation, the
reaction mixture was diafiltrated and concentrated in 400 mlP B S
using a vivaspin 0.5 ml concentrator column (30 kDa cut off,
Vivascience). The KLH-glutaraldehyde concentrate (400 ml) was
incubated with 600 ml of 1.2 mg RNase 7 in PBS for 1 h at room
temperature with gentle rotation. The reaction was stopped by the
addition of 5 ml 1 M Tris (pH 8.0). 500 mlo f0 . 6m gR N a s e7i n
PBS was added and the preparation was divided into one 450 ml
aliquot for initial immunization and three 350 mla l i q u o t sf o r
booster immunization of a goat. The immunization was carried
out by the ‘‘ZIKA-Kaninchenbetrieb’’ (Gottin, Germany). We
generated an RNase 7 affinity column to selectively isolate RNase
7 specific antibodies from the serum. Therefore, 1.5 mg of
recombinant RNase 7 was coupled to a 1 ml HiTrap NHS-
activated column (Amersham Pharmacia Biotech) according to
the manufacturer’s protocol. 500 ml of goat anti-RNase 7 serum
was loaded onto the affinity column and the column was washed
with 10 mM sodium phosphate buffer, pH 7.3. Low-affinity
antibodies were eluted using 1 M NaCl (pH 7) and high-affinity
RNase 7 antibodies were eluted using 200 mM glycine (pH 3),
immediately neutralized with 1 M Tris (pH 7.5) and dialfiltered
against PBS.
ELISA
96-well immunoplates (MaxiSorp
TM, Nunc) were coated at
37uC for 1 h with 50 ml affinity-purified goat anti-RNase 7
antibody diluted 1:1000 to 1 mg?ml
21 in 0.05 M carbonate buffer,
pH 9.6. Subsequently, wells were blocked with 200 ml 1% bovine
serum albumin in PBS for 10 min at room temperature. After
washing three times with 200 ml PBS+0.1% Tween 20, 50 ml per
well of cell culture supernatants and serial dilutions of natural skin-
derived RNase 7 in cell culture medium were incubated for
30 min at room temperature. Plates were washed three times with
PBS+0.1% Tween 20 and wells were incubated for 30 min at
room temperature with 50 ml of biotinylated goat anti-RNase 7
antibody diluted 1:7500 to 1.3 mg?ml
21 in PBS+0.1% Tween 20.
Plates were washed again three times with PBS+0.1% Tween and
filled with 50 ml?well
21 of Streptavidin-POD (Roche Diagnostics;
1:10000 in PBS+0.1% Tween 20). The plates were then incubated
for 30 min at room temperature, washed six times as described
above, and incubated with the development agent 2,29-azino-bis-
3-ethylbenzthiazoline-6-sulfonic acid (ABTS; Roche Diagnostics)
for 15 min at room temperature in the dark. Absorbance was
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Tecan, Crailsheim, Germany). The psoriasin and hBD-2 ELISAs
were performed as previously described [18,43].
Western blot
Stratum corneum derived from the heel of healthy individuals
was extracted with acidic ethanolic citrate buffer as previously
described [44]. Stratum corneum extract was mixed with 4x
NuPAGE LDS Sample Buffer (Invitrogen) and 0.5 mgo ft h i s
extract was separated onto a NuPAGE 4-12% Bis-Tris Gel
(Invitrogen). Proteins were transferred to a Protran-nitrocellulose
membrane (Schleicher & Schuell BioScience), blocked for 1 h in
blocking buffer (5% (w?v
21) nonfat powdered milk in
PBS+0.05% Tween), then incubated for 18 h at 4uCi n3 %
(w?v
21)n o n f a tp o w d e r e dm i l ki nP B S +0.05% Tween containing
RNase 7 affinity-purified antibody (10 mg?ml
21). The membrane
was washed with PBS+0.05% Tween six times for 5 min each,
then incubated for 1 h in 3% (w?v
21) nonfat powdered milk in
PBS+0.05% Tween containing 1:20000 dilution of mouse anti-
goat IgG HRP conjugate (Dianova). After another six washes, the
membrane was incubated for 5 min with chemiluminescent
peroxidase substrate (Sigma) and visualized using a Diana III
cooled CCD-camera imaging system (Raytest, Straubenhardt,
Germany).
Immunohistochemistry
To localize the protein expression of RNase 7 in human skin
biopsies, immunhistochemical staining was performed. Therefore
5 mm vertical paraffin sections were deparaffinised and rehydrated
followed by heat-induced antigen retrieval in 0.01 M citrate buffer
(pH 6.0). The slides were blocked with normal rabbit serum (1:5,
Dako Cytomation) and incubated for 60 min with the self-
generated polyclonal goat anti-RNase 7 antibody (10 mg?ml
21,
1:400). Subsequently, the sections were incubated with a
biotinylated rabbit anti-goat IgG antibody (1:500, Dianova)
followed by incubation with Vector Universal ABC Alkaline
Phophatase Substrate Kit (Vector), development with Vector
NovaRED Substrate (Vector) and counterstaining with hematox-
ylin. Negative control straining was performed by using pre-
immune serum.
Antimicrobial and ribonuclease assay
Natural skin-derived RNase 7 was purified from skin extracts as
previously described [25] and used for a standard antimicrobial
microdilution assay as described previously [29]. Briefly, test
organisms were incubated with various concentrations of RNase 7
in 10 mM sodium phosphate buffer (pH 7.4 or the indicated pH
conditions) containing 1% (v?v
21) trypticase soy broth for 3 h at 37
uC. The antibiotic activity of RNase 7 was analyzed by plating
serial dilutions of the incubation mixtures and determining the
number of colony-forming units (CFUs) the following day.
The ribonuclease activity of recombinant RNase 7 was
determined against a standard yeast tRNA substrate as described
previously [25].
Antimicrobial activity of stratum corneum extracts
Stratum corneum derived from the heel of healthy individuals
was extracted as previously described [44] and diafiltered against
10 mM sodium phosphate buffer (pH 7.4). ELISA analysis
revealed concentrations of 7–63 mg RNase 7 per gram stratum
corneum. E. faecium (ATCC 6057; 4610
3/ml) was incubated with
1 ml of stratum corneum in 50 ml 10 mM sodium phosphate buffer
(pH 7.4). The same experiment was carried out with application of
10 ml R7 antibody (10 mg?ml
21) or equivalent concentrations of
irrelevant antibodies (antibodies derived from goat preimmune
serum). Killing activity was analyzed by plating serial dilutions of
the incubation mixture and counting the colony-forming units
(CFU) the following day.
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